APA

Varghese A. M., Howard D. R., Pocock C., Rawstron A. C., Follows G., McCarthy H., Dearden C., Fegan C., Milligan D., Smith A. F., Gregory W. & Hillmen P. (20170608). Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. : British journal of haematology.

Chicago

Varghese Abraham M, Howard Dena R, Pocock Christopher, Rawstron Andy C, Follows George, McCarthy Helen, Dearden Claire, Fegan Christopher, Milligan Donald, Smith Alexandra F, Gregory Walter and Hillmen Peter. 20170608. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. : British journal of haematology.

Harvard

Varghese A. M., Howard D. R., Pocock C., Rawstron A. C., Follows G., McCarthy H., Dearden C., Fegan C., Milligan D., Smith A. F., Gregory W. and Hillmen P. (20170608). Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. : British journal of haematology.

MLA

Varghese Abraham M, Howard Dena R, Pocock Christopher, Rawstron Andy C, Follows George, McCarthy Helen, Dearden Claire, Fegan Christopher, Milligan Donald, Smith Alexandra F, Gregory Walter and Hillmen Peter. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. : British journal of haematology. 20170608.